At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 54 enrolled

Drug / intervention

Lenalidomide +1 moredrug

Likely dose

Lenalidomide 10 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00294632

NCT00294632Phase 2Completed

Compare CT.gov

Lenalidomide and Rituximab Treatment of Relapsed Mantle Cell Lymphoma and Diffuse Large B-Cell Non-Hodgkin's Lymphoma, Transformed Large Cell Lymphoma, and/or Grade 3 Follicular Lymphoma (Follicular Cleaved Large Cell Lymphoma or Follicular Non-Cleaved Large Cell Lymphoma (RV-LYM-PI-0056)

M.D. Anderson Cancer Center·interventional·Posted Feb 22, 2006·Updated Feb 24, 2020

In Brief

A Phase 2 clinical trial evaluating Lenalidomide and Rituximab for Lymphoma. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to find the highest tolerable dose of the drug lenalidomide (Revlimid, lenalidomide) that can be given with Rituxan® (rituximab) in the treatment of relapsed mantle cell lymphoma. The safety and effectiveness of this combination treatment will also be studied in both mantle cell lymphoma and diffuse large B-cell non-Hodgkin's lymphoma, transformed large cell lymphoma, and/or Grade 3 follicular lymphoma (follicular cleaved large cell lymphoma or follicular non-cleaved large cell lymphoma).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsLymphoma

CountriesUnited States

CollaboratorsCelgene Corporation

Timeline

Phase 2CompletedFinished

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartFeb 2006

First PostedFeb 2006

Primary CompletionFeb 2016

TodayJul 2026

First PostedFeb 22, 2006

Enrollment StartFeb 1, 2006

Primary CompletionFeb 1, 2016

TodayJul 2, 2026

Enrollment to primary: 10 yearsPosted 20.4 years ago

Interventions

Lenalidomidedrug

Starting Dose 10 mg By Mouth Daily on Days 1-21

Rituximabdrug

375 mg/m\^2 By Vein Weekly for 4 Weeks